MX2023006189A - Formulacion oral de conjugado de material biologicamente activo que tiene acoplada un resto de biotina, un resto de acido graso o una combinacion de estos. - Google Patents
Formulacion oral de conjugado de material biologicamente activo que tiene acoplada un resto de biotina, un resto de acido graso o una combinacion de estos.Info
- Publication number
- MX2023006189A MX2023006189A MX2023006189A MX2023006189A MX2023006189A MX 2023006189 A MX2023006189 A MX 2023006189A MX 2023006189 A MX2023006189 A MX 2023006189A MX 2023006189 A MX2023006189 A MX 2023006189A MX 2023006189 A MX2023006189 A MX 2023006189A
- Authority
- MX
- Mexico
- Prior art keywords
- active material
- biologically active
- moiety
- combination
- fatty acid
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 4
- 239000011149 active material Substances 0.000 title abstract 4
- 229960002685 biotin Drugs 0.000 title abstract 2
- 235000020958 biotin Nutrition 0.000 title abstract 2
- 239000011616 biotin Substances 0.000 title abstract 2
- 125000005313 fatty acid group Chemical group 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica oral que comprende (i) un material biológicamente activo conjugado en el que un material biológico activo se conjuga con un resto de biotina, un resto de ácido graso o una combinación de estos, y (ii) un excipiente, donde la tasa de absorción del material biológicamente activo aumenta notablemente, por lo que los fármacos convencionales difíciles de administrar por vía oral, tales como proteínas o péptidos, pueden administrarse por vía oral.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200163362 | 2020-11-27 | ||
PCT/KR2021/017802 WO2022114908A1 (ko) | 2020-11-27 | 2021-11-29 | 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023006189A true MX2023006189A (es) | 2023-07-04 |
Family
ID=81756220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023006189A MX2023006189A (es) | 2020-11-27 | 2021-11-29 | Formulacion oral de conjugado de material biologicamente activo que tiene acoplada un resto de biotina, un resto de acido graso o una combinacion de estos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240000803A1 (es) |
EP (1) | EP4252781A1 (es) |
JP (1) | JP2023551480A (es) |
KR (1) | KR20220075189A (es) |
CN (1) | CN116940384A (es) |
AU (1) | AU2021385222A1 (es) |
CA (1) | CA3200351A1 (es) |
GB (1) | GB2616223A (es) |
IL (1) | IL303023A (es) |
MX (1) | MX2023006189A (es) |
WO (1) | WO2022114908A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569901B2 (en) * | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
EP1883395A4 (en) * | 2005-05-23 | 2012-07-04 | Sdg Inc | LIPID CONSTRUCTION FOR THE ADMINISTRATION OF INTERFERON TO A MAMMAL |
PL1767545T3 (pl) * | 2005-09-22 | 2010-04-30 | Biocompatibles Uk Ltd | Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy |
US8962015B2 (en) * | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
EP2910571B1 (en) * | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
US10501546B2 (en) * | 2015-09-04 | 2019-12-10 | The California Institute For Biomedical Research | Insulin immunoglobulin fusion proteins |
-
2021
- 2021-11-29 CN CN202180092430.9A patent/CN116940384A/zh active Pending
- 2021-11-29 AU AU2021385222A patent/AU2021385222A1/en active Pending
- 2021-11-29 EP EP21898733.7A patent/EP4252781A1/en active Pending
- 2021-11-29 US US18/039,184 patent/US20240000803A1/en active Pending
- 2021-11-29 KR KR1020210167781A patent/KR20220075189A/ko not_active Application Discontinuation
- 2021-11-29 WO PCT/KR2021/017802 patent/WO2022114908A1/ko active Application Filing
- 2021-11-29 IL IL303023A patent/IL303023A/en unknown
- 2021-11-29 CA CA3200351A patent/CA3200351A1/en active Pending
- 2021-11-29 JP JP2023532339A patent/JP2023551480A/ja active Pending
- 2021-11-29 GB GB2309252.1A patent/GB2616223A/en active Pending
- 2021-11-29 MX MX2023006189A patent/MX2023006189A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN116940384A (zh) | 2023-10-24 |
GB2616223A (en) | 2023-08-30 |
US20240000803A1 (en) | 2024-01-04 |
KR20220075189A (ko) | 2022-06-07 |
IL303023A (en) | 2023-07-01 |
EP4252781A1 (en) | 2023-10-04 |
JP2023551480A (ja) | 2023-12-08 |
WO2022114908A1 (ko) | 2022-06-02 |
CA3200351A1 (en) | 2022-06-02 |
GB2616223A9 (en) | 2024-06-05 |
AU2021385222A1 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2626368A3 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
BR0011772A (pt) | Conjugado de droga-oligÈmero, composição farmacêutica, método de solubilização de uma droga em uma microemulsão, e, métodos para fornecer um conjugado de droga ativa - hidrófilo e um conjugado de droga ativa - peg a um sìtio de um indivìduo | |
JPS6245535A (ja) | 鼻、口、舌下および膣腔の粘膜から薬剤を供給する吸収増強剤としてのアシルカルニチン類 | |
HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
NZ580967A (en) | Composition comprising a bile salt and an effervescent excipient component for transmucosal delivery of polypeptides | |
MX2010002448A (es) | Formulacion liquida del g-csf conjugado. | |
EP1778209B8 (en) | Methods and compositions for oral delivery of fts | |
KR830002510A (ko) | 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물 | |
HUP0400115A2 (hu) | Gyógyászati készítmény fulvesztrant intramuszkuláris beadására | |
NO20042055L (no) | Tymosinalfa 1-peptid/polymerkonjugater | |
ATE342276T1 (de) | Nährstoffe aus sojabohnenprotein | |
GB2616223A9 (en) | Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto | |
BRPI0415322A (pt) | composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina | |
WO2004028457A3 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY | |
US10391154B2 (en) | Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma | |
RU2322996C2 (ru) | Ранозаживляющий биопрепарат в виде геля | |
ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
ITMI980356A1 (it) | Composizioni orali a basso dosaggio di proteine citotossiche | |
US10568866B1 (en) | Composition and its use for increasing innate immune health | |
DE69803772T2 (de) | Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung | |
RU2234939C1 (ru) | Лекарственный препарат сублингвальных таблеток, содержащий интерферон-альфа, и способ его получения | |
CN116102633A (zh) | 一种抑菌洗发水 | |
KR20230127957A (ko) | 호흡기 질환 예방 및 치료용 약학 조성물 | |
PT1100476E (pt) | Formulacoes para uma administracao transdermica de fenoldopam | |
KR20010006361A (ko) | 경점막 투여 제제 |